BACKGROUND: PREDICT (http://www.predict.nhs.uk) is a prognostication and treatment benefit tool for early @entity0 (EBC). The aim of this study was to incorporate the prognostic effect of KI67 status in a new version (v3), and compare performance with the Predict model that includes @entity1722 status (v2). METHODS: The validation study was based on 1,726 @entity1 with EBC treated in Nottingham between 1989 and 1998. KI67 positivity for PREDICT is defined as >10% of @entity5 cells staining positive. ROC curves were constructed for Predict models with (v3) and without (v2) KI67 input. Comparison was made using the method of DeLong. RESULTS: In 1274 ER+ @entity1 the predicted number of events at 10  years increased from 196 for v2 to 204 for v3 compared to 221 observed. The area under the ROC curve (AUC) improved from 0.7611 to 0.7676 (p   =   0.005) in ER+ @entity1 and from 0.7546 to 0.7595 (p   =   0.0008) in all 1726 @entity1 (ER+ and ER-). CONCLUSION: Addition of KI67 to PREDICT has led to a statistically significant improvement in the model performance for ER+ @entity1 and will aid clinical decision making in these @entity1 . Further studies should determine whether other markers including gene expression profiling provide additional prognostic information to that provided by PREDICT.

Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
